Rx Adherence Lower for Patients New to Diabetes Therapy

This article originally appeared here.
Share this content:
Rx Adherence Lower for Patients New to Diabetes Therapy
Rx Adherence Lower for Patients New to Diabetes Therapy

MONDAY, Jan. 19, 2015 (HealthDay News) -- Factors associated with adherence to medications for treatment of diabetes include experience with diabetes therapy and related costs, thus efforts to reduce out-of-pocket costs may result in higher adherence, according to research findings published online Jan. 8 in Diabetes Care.

M. Sue Kirkman, M.D., from the University of North Carolina School of Medicine in Chapel Hill, and colleagues conducted a retrospective analysis of a pharmacy claims database to examine patient, medication, and prescriber factors associated with antidiabetic medication adherence. Data were included for more than 200,000 patients treated with noninsulin medications. A modified adherence measure was used that accounted for changing therapies.

The researchers found that adherence, defined as a medication possession ratio ≥0.8, was 69 percent. Independent correlations were seen for adherence with older age, male gender, higher education, higher income, use of mail order versus retail pharmacies, primary care versus nonendocrinology specialist prescribers, higher daily pill burden, and lower out-of-pocket costs. The likelihood of adherence was significantly lower for patients who were new to diabetes therapy.

"For all patients, efforts to reduce out-of-pocket costs and encourage use of mail order pharmacies may result in higher adherence," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; the study was partially funded by Amylin Pharmaceuticals, Novo Nordisk, and Sanofi.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »